Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Pavan, Vajjah"'
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTInnovative approaches in the design of T cell-engaging (TCE) molecules are ushering in a new wave of promising immunotherapies for the treatment of cancer. Their mechanism of action, which generates an in trans interaction to create a synthet
Externí odkaz:
https://doaj.org/article/3e72b1cc99f146d7aaec4efa9cd6c54c
Publikováno v:
The Journal of Clinical Pharmacology. 63:435-444
Systemic lupus erythematosus (SLE) is a systemic, autoimmune disease characterized by chronic inflammation and organ damage. Dapirolizumab pegol inhibits CD40 ligand (CD40L) and is currently undergoing phase 3 trials for the treatment of SLE. To desc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c37d05bab569412d18975ee0a4982ea
https://doi.org/10.1002/jcph.2188
https://doi.org/10.1002/jcph.2188
Autor:
Ralph Adams, Asher Maroof, Terry Baker, Alastair D. G. Lawson, Ruth Oliver, Ross Paveley, Steve Rapecki, Stevan Shaw, Pavan Vajjah, Shauna West, Meryn Griffiths
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Interleukin (IL)-17A is a key driver of inflammation and the principal target of anti-IL-17 therapeutic monoclonal antibodies. IL-17A, and its structurally similar family member IL-17F, have been shown to be functionally dysregulated in certain human
Externí odkaz:
https://doaj.org/article/b1dbe735c4a147d884a03b1106dffb94
Autor:
Gary Burgess, Malcolm Boyce, Margaret Jones, Lars Larsson, Mark J. Main, Frazer Morgan, Peter Phillips, Alison Scrimgeour, Foteini Strimenopoulou, Pavan Vajjah, Miren Zamacona, Roger Palframan
Publikováno v:
EBioMedicine, Vol 35, Iss , Pp 67-75 (2018)
Background: Interleukin-13 (IL-13) is a key mediator of T-helper-cell-type-2 (Th-2)-driven asthma, the inhibition of which may improve treatment outcomes. We examined the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of VR942, a dry-
Externí odkaz:
https://doaj.org/article/4112209b44a549208dede8f273b97447
Autor:
H Edwards, Ash Maroof, A El Baghdady, Xuan Li, Lucian Ionescu, Sandra Garcet, C Mistry, Pavan Vajjah, B Dizier, James G. Krueger, Mark I L Watling, M Page, Ruth Oliver, Sophie Glatt, Dominique Baeten, Stevan Shaw
Publikováno v:
British journal of dermatology. Wiley-Blackwell
Background: Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, which is currently under investigation for treatment of moderate-to-severe plaque psoriasis. Maintenance dosing every 4 weeks is well est
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c26482ef1ae45a1fc65b42dc0b19857d
https://pure.amc.nl/en/publications/bimekizumab-for-the-treatment-of-moderatetosevere-plaque-psoriasis(2fbd1a03-ee73-4a58-af39-d52b4a5db98c).html
https://pure.amc.nl/en/publications/bimekizumab-for-the-treatment-of-moderatetosevere-plaque-psoriasis(2fbd1a03-ee73-4a58-af39-d52b4a5db98c).html
Autor:
Terry Baker, Stevan Shaw, Meryn Griffiths, Steve Rapecki, Alastair D. G. Lawson, Ralph Adams, Shauna West, Ruth Oliver, Ross A. Paveley, Pavan Vajjah, Asher Maroof
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology
Frontiers in Immunology
Interleukin (IL)-17A is a key driver of inflammation and the principal target of anti-IL-17 therapeutic monoclonal antibodies. IL-17A, and its structurally similar family member IL-17F, have been shown to be functionally dysregulated in certain human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::768ee05600e69541ddf3290aebb7d246
https://doi.org/10.3389/fimmu.2020.01894
https://doi.org/10.3389/fimmu.2020.01894
Autor:
Frazer Giles Morgan, Mark Jonathan Main, Peter Phillips, Pavan Vajjah, Roger Palframan, Malcolm Boyce, Foteini Strimenopoulou, Miren Zamacona, Lars Larsson, Margaret Jones, Gary Burgess, Alison Scrimgeour
Publikováno v:
EBioMedicine. 35
Background Interleukin-13 (IL-13) is a key mediator of T-helper-cell-type-2 (Th-2)-driven asthma, the inhibition of which may improve treatment outcomes. We examined the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of VR942, a dry-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a94c824823103326f3fbd6734ffdf0
https://pubmed.ncbi.nlm.nih.gov/30120079
https://pubmed.ncbi.nlm.nih.gov/30120079
Autor:
Leon Aarons, Trevor N. Johnson, Pavan Vajjah, Farzaneh Salem, Amin Rostami-Hodjegan, Kayode Ogungbenro
Publikováno v:
The Journal of Clinical Pharmacology. 54:311-317
A new approach for calculation of sample size in pediatric clinical pharmacokinetic studies was suggested based on desired precision for a pharmacokinetic parameter of interest. The estimate of variability for sample size calculations could be obtain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d78c93a6c067295f737a46fb4ecdd1f9
https://doi.org/10.1002/jcph.206
https://doi.org/10.1002/jcph.206
Autor:
Stephen B. Duffull, Pavan Vajjah
Publikováno v:
Pharmaceutical Statistics. 11:503-510
The T-optimality criterion is used in optimal design to derive designs for model selection. To set up the method, it is required that one of the models is considered to be true. We term this local T-optimality. In this work, we propose a generalisati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc82f293dd2dfa57a17cb8e6a7896c0a
https://doi.org/10.1002/pst.1542
https://doi.org/10.1002/pst.1542
Autor:
Pavan Vajjah, Dominique Baeten, Sophie Glatt, Lucian Ionescu, Stevan Shaw, Foteini Strimenopoulou, Serghei Popa
Publikováno v:
Annals of the Rheumatic Diseases. 75:95.3-96
Background Bimekizumab (UCB4940) is a potent and selective monoclonal antibody inhibiting the activity of both IL-17A and IL-17F, which are key pro-inflammatory cytokines overexpressed in skin lesions of patients with psoriasis.1 Blocking both IL-17A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e80d033f60705b8e6843f7b4a982d0
https://doi.org/10.1136/annrheumdis-2016-eular.2952
https://doi.org/10.1136/annrheumdis-2016-eular.2952